Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

Ciprofloxacin Garners No UK Concessions Despite Rises

Despite the average trade price of ciprofloxacin shooting up in September, no UK price concessions were granted by the DHSC.

Market Intelligence Pricing Strategies

Canada Saves CAD2bn Through Pricing Deal

A five-year agreement between the Canadian Generic Pharmaceutical Association and the pan-Canadian Pharmaceutical Alliance has helped to save close to CAD2bn in prescription drug costs in Canada. However, the CGPA has expressed concern over price cuts that are forcing Canada increasingly to rely on supply from lower-cost jurisdictions such as China and India.

Canada BioPharmaceutical

Ireland Eyes ‘Conservative’ Savings Of €1bn Through Increased Uptake

Off-patent industry association Medicines for Ireland believes the country could see ten-figure savings over the next five years if its penetration rates are brought in line with fellow EU member states, as well as the UK.

Biosimilars Generic Drugs

AAM Sees ‘Red Flag’ In IQVIA Biosimilars Report

While the latest IQVIA data points to accelerated uptake of US biosimilars over the next five years, with associated increases in spending and savings, local off-patent industry association the AAM says the report raises a “red flag” over long-term market sustainability.

Market Intelligence Biosimilars

US Saves $313bn From Generics And $2.2bn From Biosimilars

The AAM’s 2019 report titled ‘Securing Our Access & Savings’ throws light on the monumental savings and benefits of generics and biosimilars for US patients and other stakeholders. The report urges policymakers to act to address obstacles to the off-patent industry and brings industry’s COVID-19 response in perspective again.

United States Market Intelligence

Sandoz Sees Revolution In US Biosimilars Market

Five years on from the first US biosimilar approval, the country’s biosimilars market is starting to fulfil its potential, in part driven by a recent oncology “revolution” according to Sandoz’ Sheila Frame.

Biosimilars United States
See All
UsernamePublicRestriction

Register